All In Biotech

Drug Trial Radar · NCT00390221

Safety and Efficacy Study of Daclizumab High Yield Process (DAC HYP) to Treat Relapsing-Remitting Multiple Sclerosis

Multicenter, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Safety and Efficacy of Daclizumab HYP (DAC HYP) as a Monotherapy Treatment in Subjects With Relapsing-Remitting Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jul 11, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 621 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

621

Actual

Start

Feb 2008

Primary completion

May 2011

Study completion Aug 2011

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
Collaborators
AbbVie
First posted
Oct 19, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to determine whether DAC HYP, when compared to placebo, is effective in reducing the rate of relapses between baseline and Week 52. The secondary objectives are to determine whether DAC HYP is effective in reducing the number of new gadolinium (Gd)-enhancing lesions, reducing the number of new or newly-enlarging T2 hyperintense lesions, reducing the proportion of participants with relapses, and improving quality of life.

Conditions

  • Relapsing-Remitting Multiple Sclerosis

Interventions

  • BIIB019 (Daclizumab High Yield Process)Biological

    SC injection

  • PlaceboDrug

    Placebo SC injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adjusted Annualized Relapse Rate Between Baseline and Week 52Time frame: Baseline through Week 52

Locations

56 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Brno, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Pilsen, Czechia

  • Research Site

    Teplice, Czechia

  • Research Site

    Erlangen, Germany

  • Research Site

    Marburg, Germany

  • Research Site

    Osnabrück, Germany

  • Research Site

    Regensburg, Germany

  • Research Site

    Rostock, Germany

  • Research Site

    Budapest, Hungary

  • Research Site

    Debrecen, Hungary

  • Research Site

    Esztergom, Hungary

  • Research Site

    Győr, Hungary

  • Research Site

    Kecskemét, Hungary

  • Research Site

    Miskolc, Hungary

  • Research Site

    Nyíregyháza, Hungary

  • Research Site

    Siófok, Hungary

  • Research Site

    Zalaegerszeg, Hungary

  • Research Site

    Andra-Pradeash, India

  • Research Site

    Bangalore, India

  • Research Site

    Chennai, India

  • Research Site

    Kolkata, India

  • Research Site

    Mumbai, India

  • Research Site

    Rajasthan, India

  • Research Site

    Visakhapatnam, India

  • Research Site

    Bialystok, Poland

  • Research Site

    Gdansk, Poland

  • Research Site

    Katowice, Poland

  • Research Site

    Krakow, Poland

  • Research Site

    Lodz, Poland

  • Research Site

    Lublin, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Kazan', Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Samara, Russia

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.